Pharma Exclusives Pressreleases
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome
Thursday, July 10, 2025Biogen Inc and Stoke Therapeutics Inc Nasdaq STOK a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine today announced the presentation of data from an analysis that informed the design
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
Wednesday, July 09, 2025Longeveron Inc a clinical stage regenerative medicine biotechnology company developing cellular therapies for lifethreatening and chronic agingrelated conditions today announced that the US Food and Drug Administration
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth
Wednesday, July 09, 2025Merck known as MSD outside of the United States and Canada and Verona Pharma plc Nasdaq VRNA Verona Pharma a biopharmaceutical company focused on respiratory diseases today announced that the companies
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
Wednesday, July 09, 2025Eli Lilly and Company announced today that the US Food and Drug Administration FDA has approved a label update with a new recommended titration dosing schedule for Kisunla donanemabazbt
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
Tuesday, July 08, 2025Eton Pharmaceuticals Inc an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases today announced the Companys New Drug Application NDA for ET a proprietary patented
Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
Monday, July 07, 2025Orchard Therapeutics a Kyowa Kirin company today announced the last patient has been treated in a registrational trial evaluating the efficacy and safety of OTL an investigational hematopoietic
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
Monday, June 30, 2025Moderna Inctoday announced positive results from a Phase efficacy study P evaluating the relative vaccine efficacy rVE against influenza illness of mRNA the Companys seasonal influenza flu vaccine candidate
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Monday, June 30, 2025Biogen Inc announced the initiation of dosing in the global clinical study PROMINENT The Phase study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
Monday, June 30, 2025Revolution Medicines Inc a latestage clinical oncology company developing targeted therapies for patients with RASaddicted cancers and Summit Therapeutics Inc Nasdaq SMMT a biopharmaceutical oncology company
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
Monday, June 30, 2025AbbVieand Capstan Therapeutics Inc a clinicalstage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs today announced a definitive agreement under which AbbVie will acquire Capstan
